Document is current
Any future updates will be listed below
-
Authors
Chithelen, Janice
Lovett, David H.
Wang, Kevin https://orcid.org/0009-0000-3441-7953
Torres Yanagisawa, Akari E.
Caccin, Farah N. M. https://orcid.org/0009-0008-3900-1779
Iketani, Sho https://orcid.org/0000-0002-3733-9556
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI171401)
- License Information
-
More Information
Article History
Received: 30 October 2025
Accepted: 11 May 2026
First Online: 19 May 2026
Competing interests
: S.I. is an inventor on patent applications related to monoclonal antibodies against SARS-CoV-2 and inhibitors against the SARS-CoV-2 3CL protease. S.I. has previously received funding through sponsored research agreements with Enanta Pharmaceuticals, Inc., Shionogi & Co., Ltd., and Regeneron Pharmaceuticals for SARS-CoV-2 studies. The remaining authors declare no competing interests.
